Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

被引：0

作者：

Kalincik, T. ^{[1
]}

Jokubaitis, V. ^{[2
]}

Spelman, T. ^{[2
]}

Horakova, D. ^{[3
,4
,5
]}

Havrdova, E. ^{[3
,4
,5
]}

Trojano, M. ^{[6
]}

Lechner-Scott, J. ^{[7
]}

Lugaresi, A. ^{[8
]}

Prat, A. ^{[9
]}

Girard, M. ^{[9
]}

Duquette, P. ^{[9
]}

Grammond, P. ^{[10
]}

Solaro, C. ^{[11
]}

Grand'Maison, F. ^{[12
]}

Hupperts, R. ^{[13
]}

Prevost, J. ^{[14
]}

Sola, P. ^{[15
]}

Ferraro, D. ^{[15
]}

Terzi, M. ^{[16
]}

Butler, E. ^{[17
]}

Slee, M. ^{[18
]}

Kermode, A. ^{[19
]}

Fabis-Pedrini, M. ^{[19
]}

McCombe, P. ^{[20
]}

Barnett, M. ^{[21
]}

Shaw, C. ^{[22
]}

Hodgkinson, S. ^{[23
]}

Butzkueven, H. ^{[2
]}

机构：

[1] Royal Melbourne Hosp, Dept Neurol, CORe, Melbourne, Vic, Australia

[2] Univ Melbourne, Dept Med, Melbourne, Vic, Australia

[3] Gen Univ Hosp, Dept Neurol, Prague, Czech Republic

[4] Gen Univ Hosp, Ctr Clin Neurosci, Prague, Czech Republic

[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[6] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

[7] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia

[8] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy

[9] Hop Notre Dame De Bon Secours, Montreal, PQ, Canada

[10] CISSS Chaudiere Appalache, Levis, PQ, Canada

[11] Osped PA Micone, Genoa, Italy

[12] Neuro Rive Sud, Quebec City, PQ, Canada

[13] Zuyderland Ziekenhuis, Sittard, Netherlands

[14] CSSS St JErUme, St Jerome, PQ, Canada

[15] Univ Modena, Dept Biomed Metab & Neurosci, Modena, Italy

[16] 19 Mayis Univ, Fac Med, Samsun, Turkey

[17] Monash Med Ctr, Melbourne, Vic, Australia

[18] Flinders Univ S Australia, Adelaide, SA, Australia

[19] Univ Western Australia, Perth, WA, Australia

[20] Univ Queensland, Brisbane, Qld, Australia

[21] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[22] Geelong Hosp, Geelong, Vic, Australia

[23] Liverpool Hosp, Sydney, NSW, Australia

来源：

MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷

基金：

加拿大健康研究院;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1138

引用

页码：596 / 597

页数：2

共 50 条

[41] Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal
Pinheiro, Bernardete
Guerreiro, Rita
Costa, Joao
Miguel, Luis Silva
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 484 - 491
[42] Effect of Fingolimod and Interferon β-1α in Children With Multiple Sclerosis
Zhao, Ying
AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (01) : E99 - E101
[43] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, Jeffrey A.
Barkhof, Frederik
Comi, Giancarlo
Hartung, Hans-Peter
Khatri, Bhupendra O.
Montalban, Xavier
Pelletier, Jean
Capra, Ruggero
Gallo, Paolo
Izquierdo, Guillermo
Tiel-Wilck, Klaus
de Vera, Ana
Jin, James
Stites, Tracy
Wu, Stacy
Aradhye, Shreeram
Kappos, Ludwig
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05): : 402 - 415
[44] Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Kalincik, Tomas
Brown, J. William L.
Robertson, Neil
Willis, Mark
Scolding, Neil
Rice, Claire M.
Wilkins, Alastair
Pearson, Owen
Ziemssen, Tjalf
Hutchinson, Michael
McGuigan, Christopher
Jokubaitis, Vilija
Spelman, Tim
Horakova, Dana
Havrdova, Eva
Trojano, Maria
Izquierdo, Guillermo
Lugaresi, Alessandra
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Grammond, Pierre
Alroughani, Raed
Pucci, Eugenio
Sola, Patrizia
Hupperts, Raymond
Lechner-Scott, Jeannette
Terzi, Murat
Van Pesch, Vincent
Rozsa, Csilla
Grand'Maison, Francois
Boz, Cavit
Granella, Franco
Slee, Mark
Spitaleri, Daniele
Olascoaga, Javier
Bergamaschi, Roberto
Verheul, Freek
Vucic, Steve
McCombe, Pamela
Hodgkinson, Suzanne
Sanchez-Menoyo, Jose Luis
Ampapa, Radek
Simo, Magdolna
Csepany, Tunde
Ramo, Cristina
Cristiano, Edgardo
Barnett, Michael
Butzkueven, Helmut
Coles, Alasdair
LANCET NEUROLOGY, 2017, 16 (04): : 271 - 281
[45] Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab
Ottenlinger, Florian M.
Mayer, Christoph A.
Ferreiros, Nerea
Schreiber, Yannick
Schwiebs, Anja
Schmidt, Katrin G.
Ackermann, Hanns
Pfeilschifter, Josef M.
Radeke, Heinfried H.
FRONTIERS IN PHARMACOLOGY, 2016, 7
[46] Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Alvarez-Gonzalez, Cesar
Adams, Ashok
Mathews, Joela
Turner, Benjamin P.
Giovannoni, Gavin
Baker, David
Schmierer, Klaus
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (07): : 506 - 511
[47] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Lorscheider, Johannes
Benkert, Pascal
Lienert, Carmen
Hanni, Peter
Derfuss, Tobias
Kuhle, Jens
Kappos, Ludwig
Yaldizli, Ozgur
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785
[48] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
Baroncini, D.
Ghezzi, A.
Stefanin, C.
Zaffaroni, M.
Annovazzi, P.
Baldini, S.
Comi, G.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
[49] Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk Reply
Alping, Peter
Frisell, Thomas
Svenningsson, Anders
Piehl, Fredrik
ANNALS OF NEUROLOGY, 2016, 80 (05) : 791 - 792
[50] Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients
Kowarik, M. C.
Astling, D.
Lepennetier, G.
Ritchie, A.
Hemmer, B.
Owens, G. P.
Bennett, Jeffrey L.
NEUROTHERAPEUTICS, 2021, 18 (01) : 364 - 377

← 1 2 3 4 5 →